From what I'm hearing, there will be significant profits to be made in Europe. The company has already announced plans to price Dyloject at a significant premium to the current agent. Pharmacoeconomic studies suggest ~50 pounds sterling savings compared with the competitor, which needs to be infused.
I don't expect a huge pop on European approval...as you say, the US market tends to treat this as a nonevent. However, I actually think JAV is underestimating the market at $75 million (predicated on taking half the market share from the infused product). Dyloject should take substantially more market share than that away from the inferior product. Extended infusion is cumbersome and costly.
I'm not hearing anyone getting too excited about European approval. IN ketamine is the reward here, and it's about as low-risk as you can get in biotech. US approval of Dyloject (which should be a shoe-in) is another reward.
Plus JAV remains substantially undervalued in comparison with competitors in the pain space.
I guess people would rather take flyers on DNDNs and MCUs than on low-risk, boring products.
Would be nice if JAV got back up to its 52-week highs, though.
